Clinical Trials

43 enrolled

Non-Squamous Non Small Cell Lung Cancer

NCT04985851 2023-12-01

To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.

90 enrolled

Small Cell Lung Carcinoma

NCT05896059 2023-06-09

A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Anlotinib as Maintenance Therapy for ES-SCLC

21 enrolled

Extensive Stage Small Cell Lung Cancer

NCT05842018 2023-05-03

Toripalimab in Combination With Chemotherapy and Antiangiogenic Agents in Patients With Non-Small Cell Lung Cancer After Failure of Immunotherapy (PD-1/L1 Inhibitors)

Non Small Cell Lung Cancer Recurrent

NCT04895930 2023-01-06

FOCUS-A

Carcinoma, Non-Small-Cell Lung

NCT05485350 2022-08-03

Anlotinib , Penpulimab Combined With SBRT for Metastatic Non-Small Cell Lung Cancer (NSCLC)

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460481 2022-07-20

Anlotinib Plus Penpulimab in Advanced Non-Small-Cell Lung Cancer Previously Treated With PD-1/PD-L1 Inhibitors

29 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05460195 2022-07-15

Sintilimab Combined With Anlotinib for Perioperative Non-small Cell Lung Cancer Based on MRD Evaluation

42 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

NCT05387109 2022-05-24

pcwaintrl

Phase 4 Unknown

41 enrolled

NSCLC

NCT05319886 2022-05-20

AP

Unknown

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05306847 2022-04-01

Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer

93 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04325763 2022-03-31

A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

315 enrolled

Carcinoma, Non-Small-Cell Lung

NCT05218759 2022-02-01

Exosomes Detection for the Prediction of the Efficacy and Adverse Reactions of Anlotinib in Patients With Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04846452 2021-08-12

Sintilimab, Anlotinib Hydrochloride and Platinum-Containing Dual-Agent Chemotherapy in NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04978753 2021-07-27

the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer

54 enrolled

CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung

NCT04933175 2021-06-21

Fluzopalil in Combination With Anlotinib for Extensive Small-cell Lung Cancer

50 enrolled

Extensive Stage Small Cell Lung Cancer

NCT04882033 2021-05-11

Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Phase 1 Unknown

9 enrolled

Small Cell Lung Cancer Limited Stage

NCT04797806 2021-03-15

SAINT

206 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04731909 2021-02-10

Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer

80 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04684017 2020-12-24

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

29 enrolled

SCLC

NCT04620837 2020-11-09

Tislelizumab in Combination With Anlotinib With ES-SCLC as Maintenance Therapy After First Line Chemotherapy

25 enrolled

Small Cell Lung Carcinoma

NCT04316351 2020-07-23

Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance

60 enrolled

IIIb/IV NSCLC With T790M Positive Mutations Failed to Osimertinib Therapy

NCT04273815 2020-07-08

A Study to Evaluate the Tolerance, Pharmacokinetics and Efficacy of TQ-A3334 Tablets

Phase 1/2 Unknown

Carcinoma, Non-Small-Cell Lung

NCT04453423 2020-07-01

Combination Chemotherapy With or Without Anlotinib in the Maintenance Treatment of Non-Squamous Non-Small Cell Lung Cancer.

90 enrolled

Non-squamous Non-small-cell Lung Cancer

NCT04363255 2020-04-28

First-line Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in ES-SCLC

20 enrolled

Small Cell Lung Carcinoma

NCT04358562 2020-04-24

Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib

240 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03706287 2020-04-06

Efficacy and Safety of Anlotinib Plus Platinum Plus Pemetrexed in T790M-negative NSCLC

Phase 1/2 Unknown

62 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04314297 2020-03-19

Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study

33 enrolled

Small Cell Lung Carcinoma

NCT04234607 2020-01-22

A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)

738 enrolled

Extensive Small Cell Lung Cancer

NCT03624309 2020-01-07

Anlotinib Plus Docetaxel for the Treatment of EGFR Wild-type Advanced Non-small-cell Lung Cancer

84 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04211896 2019-12-26

Anlotinib Combined With Nivolumab for Non-Small Cell Lung Cancer

70 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03700359 2019-11-29

A Study of Lobaplatin/Etoposide With or Without Anlotinib Maintenance Therapy in Patients With ES-SCLC

60 enrolled

Small Cell Lung Carcinoma

NCT04181372 2019-11-29

A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung Cancer

50 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04164745 2019-11-15

Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung Cancer

49 enrolled

NSCLC

NCT03910127 2019-10-30

Study of TQB2450 Combined With Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（NSCLC）

Phase 1 Unknown

90 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03769805 2019-10-22

CSOAIMTOAN

83 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04124731 2019-10-11

Combination Therapy of Sintilimab and Anlotinib as a First-line Treatment in Advanced NSCLC (SUNRISE)

98 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung

NCT04073537 2019-08-29

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

386 enrolled

Squamous Non-small Cell Lung Cancer

NCT04073550 2019-08-29

Study of Anlotinib Hydrochloride Capsule in Subjects With Small Cell Lung Cancer

184 enrolled

Small Cell Lung Carcinoma

NCT03983928 2019-08-15

Study of TQB2450 Combined With Anlotinib in the Treatment of Mutation Positive Lung Cancer

Phase 1/2 Unknown

Lung Neoplasms

NCT03841136 2019-03-28

Anlotinib Combined With Etoposide and Platinum in the Treatment of Lung Cancer

70 enrolled

Small Cell Lung Carcinoma

NCT03799601 2019-01-10

ALTER-L013

Phase 4 Unknown

45 enrolled

NSCLC

NCT03780283 2018-12-21

Efficacy and Safety of Anlotinib as Maintenance Treatment After First-line Chemotherapy in SCLC

Carcinoma, Lung Neoplasms, Small Cell Lung Carcinoma

NCT03778138 2018-12-19

ALTER-L025

51 enrolled

Non-squamous Cell Non-Small Cell Lung Cancer

NCT03765775 2018-12-06

Anlotinib Plus Sintilimab for NSCLC Patients With First-generation EGFR-TKIs Drug Resistance Along With T790M Negative

20 enrolled

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03732846 2018-11-07

Anlotinib in Treatment of Recurrent Small Cell Lung Cancer

43 enrolled

Small Cell Lung Carcinoma

NCT03728374 2018-11-02

Anlotinib Hydrochloride as Second-line Therapy in Elderly Patients With EGFR Wild-type Lung Adenocarcinoma

38 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03671538 2018-09-17

Non Squamous NSCLC Patients With Anlotinib Combined With Pemetrexed and Cisplatin

62 enrolled

Non-squamous Non-small Cell Lung Cancer

NCT03672136 2018-09-14

Concurrent Chemoradiotherapy Combination With Anlotinib for Unresectable Stage III NSCLC Patients

25 enrolled